Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Polymorphisms in the Estrogen Receptor Beta Gene and Risk of Breast Cancer: No Association
Authors
Asta Försti
Chunyan Zhao
Elisabeth Israelsson
Karin Dahlman-Wright
Jan-Åke Gustafsson
Kari Hemminki
Publication date
01-06-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1024020609833

Other articles of this Issue 3/2003

Breast Cancer Research and Treatment 3/2003 Go to the issue

OriginalPaper

Progesterone Receptors A and B Differentially Affect the Growth of Estrogen-Dependent Human Breast Tumor Xenografts

OriginalPaper

Incidence of Anaemia in Breast Cancer Patients Receiving Adjuvant Chemotherapy

OriginalPaper

Ornithine Decarboxylase (ODC) as a Prognostic Factor in Operable Breast Cancer

OriginalPaper

Progesterone Receptor Expression in Medroxyprogesterone Acetate-Induced Murine Mammary Carcinomas and Response to Endocrine Treatment

OriginalPaper

Growth and Fatty Acid Metabolism of Human Breast Cancer (MCF-7) Xenografts in Nude Rats: Impact of Constant Light-Induced Nocturnal Melatonin Suppression

OriginalPaper

HER2 Codon 655 Polymorphism and Risk of Breast Cancer in African Americans and Whites
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits